Formulary Payments From Manufacturers To PBMs Reviewed By FTC
Executive Summary
Contract agreements between pharmacy benefit managers and pharmaceutical manufacturers do not typically demonstrate higher payment allowances for drugs dispensed through PBM-owned mail order pharmacies compared to retail pharmacies, according to a Federal Trade Commission report
You may also be interested in...
FTC Seeks Input On How PBM Rebating Practices Affect Drug ‘Affordability,’ Access
With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.
PBM Group Promotes Mail Order Savings, Vows Differential Co-Pays
Mail-order pharmacies could capture as much as half of the total prescription drug market if consumers applied the service to all appropriate scripts, The Lewin Group concludes in a report to PCMA
USP To Help Set Formulary Rules Under Medicare Rx Bill
The U.S. Pharmacopeia would play a central role in setting the ground rules for formularies under the Medicare prescription drug bill